Cerity Partners LLC Grows Stock Holdings in Genmab A/S (NASDAQ:GMAB)

Cerity Partners LLC raised its position in Genmab A/S (NASDAQ:GMAB - Free Report) by 344.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 55,053 shares of the company's stock after acquiring an additional 42,661 shares during the period. Cerity Partners LLC's holdings in Genmab A/S were worth $1,753,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Keybank National Association OH purchased a new stake in shares of Genmab A/S during the third quarter valued at $1,154,000. Knights of Columbus Asset Advisors LLC grew its holdings in shares of Genmab A/S by 16.8% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 5,712 shares of the company's stock valued at $201,000 after buying an additional 822 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Genmab A/S by 350.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,845 shares of the company's stock valued at $154,000 after buying an additional 3,770 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Genmab A/S by 83.3% during the third quarter. Northern Trust Corp now owns 559,044 shares of the company's stock valued at $19,717,000 after buying an additional 254,042 shares during the last quarter. Finally, HBK Sorce Advisory LLC grew its holdings in shares of Genmab A/S by 4.8% during the third quarter. HBK Sorce Advisory LLC now owns 9,139 shares of the company's stock valued at $322,000 after buying an additional 419 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on GMAB. Truist Financial reissued a "buy" rating and set a $50.00 price objective on shares of Genmab A/S in a report on Tuesday, March 26th. Citigroup lowered shares of Genmab A/S from a "neutral" rating to a "sell" rating in a report on Monday, January 22nd. BMO Capital Markets raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and upped their price target for the company from $46.00 to $48.00 in a report on Friday, February 23rd. Morgan Stanley reaffirmed an "underweight" rating on shares of Genmab A/S in a report on Tuesday, March 26th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $50.00 price target on shares of Genmab A/S in a report on Thursday, April 4th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $48.50.

Genmab A/S Trading Up 1.3 %

Shares of Genmab A/S stock traded up $0.37 during trading hours on Friday, reaching $28.70. The stock had a trading volume of 361,029 shares, compared to its average volume of 365,238. The stock's 50 day moving average is $29.38 and its 200 day moving average is $30.27. The firm has a market capitalization of $18.98 billion, a PE ratio of 29.90, a PEG ratio of 2.03 and a beta of 0.99. Genmab A/S has a twelve month low of $26.32 and a twelve month high of $42.72.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 earnings per share for the quarter, topping analysts' consensus estimates of $0.34 by $0.02. The business had revenue of $675.29 million during the quarter, compared to the consensus estimate of $678.14 million. Genmab A/S had a net margin of 26.50% and a return on equity of 18.06%. As a group, sell-side analysts predict that Genmab A/S will post 1.06 earnings per share for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.